All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

pentosan polysulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2097	37300-21-3

Description:

Molecule	Description
Synonyms: elmiron pentosan polysulfate xylan polysulfate xylan sulfate xylofuranan sulfate pentosan polysulfate sodium	A sulfated pentosyl polysaccharide with heparin-like properties. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	3 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Sept. 26, 1996	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Maculopathy	2577.83	21.04	363	3800	2143	90622141
Dry age-related macular degeneration	547.73	21.04	71	4092	185	90624099
Retinal pigmentation	163.63	21.04	22	4141	82	90624202
Off label use	142.49	21.04	210	3953	1102042	89522242
Retinal dystrophy	113.44	21.04	14	4149	20	90624264
Retinopathy	106.22	21.04	26	4137	3508	90620776
Retinal degeneration	93.60	21.04	19	4144	1090	90623194
Cystitis interstitial	90.76	21.04	20	4143	1704	90622580
Colon dysplasia	70.30	21.04	11	4152	137	90624147
Eyelid exfoliation	55.51	21.04	10	4153	302	90623982
Macular degeneration	54.35	21.04	29	4134	37941	90586343
Retinal drusen	44.08	21.04	6	4157	25	90624259
Age-related macular degeneration	41.39	21.04	9	4154	720	90623564
Neovascular age-related macular degeneration	40.00	21.04	8	4155	425	90623859
Retinal toxicity	35.41	21.04	9	4154	1413	90622871
Tuberculin test positive	30.86	21.04	10	4153	3715	90620569
Bladder pain	29.57	21.04	9	4154	2728	90621556
Cholecystitis chronic	24.59	21.04	11	4152	9815	90614469
Allodynia	23.14	21.04	6	4157	1018	90623266
Cystoid macular oedema	23.09	21.04	7	4156	2093	90622191
Choroidal neovascularisation	22.97	21.04	5	4158	402	90623882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thermophobia	63.53	36.74	9	1780	59	42619487
Adrenocorticotropic hormone deficiency	52.19	36.74	12	1777	1358	42618188
Maculopathy	44.08	36.74	10	1779	1065	42618481
Prostatic pain	42.23	36.74	8	1781	351	42619195
Appendicolith	41.52	36.74	17	1772	13439	42606107
Hypophosphataemia	40.36	36.74	19	1770	20926	42598620
Appendicitis	37.58	36.74	18	1771	20595	42598951

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Maculopathy	1422.66	19.99	221	4647	2806	110581625
Dry age-related macular degeneration	232.48	19.99	34	4834	272	110584159
Retinal pigmentation	122.93	19.99	17	4851	86	110584345
Cystitis interstitial	94.72	19.99	20	4848	1454	110582977
Retinal degeneration	81.16	19.99	18	4850	1648	110582783
Retinopathy	72.85	19.99	20	4848	4409	110580022
Colon dysplasia	66.85	19.99	12	4856	371	110584060
Thermophobia	63.09	19.99	9	4859	59	110584372
Eyelid exfoliation	55.77	19.99	10	4858	307	110584124
Off label use	52.23	19.99	164	4704	1500021	109084410
Adrenocorticotropic hormone deficiency	46.04	19.99	12	4856	2170	110582261
Prostatic pain	43.30	19.99	8	4860	291	110584140
Anal ulcer	42.91	19.99	11	4857	1865	110582566
Retinal dystrophy	42.81	19.99	6	4862	34	110584397
Appendicolith	39.74	19.99	17	4851	14238	110570193
Appendicitis	39.49	19.99	21	4847	28443	110555988
Macular degeneration	35.87	19.99	18	4850	21641	110562790
Bacteroides infection	33.68	19.99	10	4858	2909	110581522
Myasthenia gravis	33.07	19.99	17	4851	21494	110562937
Tuberculin test positive	31.43	19.99	10	4858	3658	110580773
Libido decreased	30.42	19.99	11	4857	5924	110578507
Age-related macular degeneration	28.72	19.99	7	4861	966	110583465
Hypophosphataemia	28.70	19.99	18	4850	33164	110551267
Hyperphosphataemia	28.26	19.99	14	4854	16367	110568064
Hypopituitarism	25.77	19.99	9	4859	4381	110580050
Retinal toxicity	25.02	19.99	7	4861	1652	110582779
Gonadotrophin deficiency	23.86	19.99	4	4864	82	110584349
Hypogonadism	23.75	19.99	7	4861	1987	110582444
Ventricular fibrillation	22.84	19.99	17	4851	41296	110543135
Blood phosphorus increased	22.51	19.99	12	4856	16328	110568103
Ulcer	22.19	19.99	17	4851	43099	110541332
Cholecystitis chronic	22.17	19.99	10	4858	9490	110574941
Aortic stenosis	22.05	19.99	11	4857	13048	110571383
Total lung capacity decreased	21.55	19.99	9	4859	7105	110577326
Cystoid macular oedema	21.40	19.99	7	4861	2793	110581638
Analgesic therapy	21.34	19.99	9	4859	7275	110577156
Drug therapy	21.33	19.99	9	4859	7282	110577149
Sleep disorder therapy	21.12	19.99	9	4859	7462	110576969
Neuralgia	20.44	19.99	17	4851	48461	110535970
Hyperlipidaemia	20.38	19.99	15	4853	35833	110548598
Lung opacity	20.23	19.99	10	4858	11642	110572789

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C05BA04	CARDIOVASCULAR SYSTEM VASOPROTECTIVES ANTIVARICOSE THERAPY Heparins or heparinoids for topical use
ATC	G04BX15	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Other urologicals
FDA CS	M0009496	Glycosaminoglycans
MeSH PA	D000925	Anticoagulants
MeSH PA	D006401	Hematologic Agents
FDA EPC	N0000175837	Glycosaminoglycan
CHEBI has role	CHEBI:67079	anti-inflammatory agent

Related Drugs by ATC class:

C05BA Heparins or heparinoids for topical use 2 drugs

heparinsodium apolate

G04BX Other urologicals 10 drugs

acetohydroxamic aciddapoxetinedimethyl sulfoxidemagnesium hydroxidemethenaminephenazopyridinephenyl salicylatesalicylic acidsuccinimidetiopronin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bladder pain	indication	15803009
Ulcerative cystitis	indication	111409009	DOID:13949
Urinary Tract Irritation	indication
Gastrointestinal ulcer	contraindication	40845000
Blood coagulation disorder	contraindication	64779008	DOID:1247
Heparin-induced thrombocytopenia	contraindication	73397007
Hemophilia	contraindication	90935002
Bleeding	contraindication	131148009
Arterial aneurysm	contraindication	233981004
Disease of liver	contraindication	235856003	DOID:409
Diverticulitis of gastrointestinal tract	contraindication	271366000
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Surgical procedure	contraindication	387713003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D05428	KEGG_DRUG
4021013	VANDF
C0600296	UMLSCUI
CHEMBL1201516	ChEMBL_ID
D010426	MESH_DESCRIPTOR_UI
DB00686	DRUGBANK_ID
140207-93-8	SECONDARY_CAS_RN
F59P8B75R4	UNII
134413	RXNORM
5255	MMSL
5909	MMSL
80071	MMSL
d04052	MMSL
004395	NDDF
109116008	SNOMEDCT_US
109117004	SNOMEDCT_US
372571007	SNOMEDCT_US
CHEBI:749457	CHEBI
92043424	PUBCHEM_CID
6311	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ELMIRON	HUMAN PRESCRIPTION DRUG LABEL	1	50458-098	CAPSULE, GELATIN COATED	100 mg	ORAL	NDA	25 sections
Elmiron	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4525	CAPSULE, GELATIN COATED	100 mg	ORAL	NDA	25 sections